[The efficacy of prostacyclin (PGI2) and/or OKY-046, a specific thromboxane synthetase inhibitor, in acute myocardial infarction--experimental study].
D000179:Acrylates / Q000627:therapeutic use*; D000818:Animals; D002395:Catecholamines / Q000378:metabolism; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D011464:Epoprostenol / Q000627:therapeutic use*; D008689:Methacrylates / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000188:drug therapy*; D009206:Myocardium / Q000378:metabolism; D010088:Oxidoreductases / Q000037:antagonists & inhibitors*; D011466:Prostanoic Acids / Q000378:metabolism; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
D000179:Acrylates; D002395:Catecholamines; D008689:Methacrylates; D011466:Prostanoic Acids; D011464:Epoprostenol; D010088:Oxidoreductases; D013930:Thromboxane-A Synthase; C034364:ozagrel